• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Equillium Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    6/13/25 4:05:42 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    8-K
    0001746466false00017464662025-06-122025-06-12

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 12, 2025

    Equillium, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware

    001-38692

    82-1554746

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

     

     

    2223 Avenida de la Playa

    Suite 105

    La Jolla, CA

     

     

     

    92037

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 240-1200

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

    EQ

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     


     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously disclosed, on December 13, 2024, Equillium, Inc. (the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum bid price of the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). The Company was given 180 days, or until June 11, 2025, to regain compliance with the Minimum Bid Price Requirement.

     

    On June 12, 2025, the Company received a notice from Nasdaq that the Company was granted an additional 180 calendar days, until December 8, 2025, to regain compliance with the Minimum Bid Price Requirement. The notice from Nasdaq states that if compliance with the Minimum Bid Price Requirement cannot be demonstrated by December 8, 2025, Nasdaq staff will provide written notification that the Company’s common stock will be delisted. At that time, the Company may appeal Nasdaq staff’s determination to a Nasdaq hearings panel.

    The Company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement, including such actions as a reverse stock split. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market and the Company’s common stock continues to trade on the Nasdaq Capital Market under the symbol “EQ.”

    Forward-Looking Statements

    This report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered “forward-looking statements”. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology. Forward-looking statements are based on current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from the expectations set forth in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to preliminary financial results, including the risks that the preliminary financial results reported herein reflect information available to the Company only at this time and may differ from actual results, including in connection with the Company’s completion of financial closing procedures, risks and uncertainties associated with the Company’s business and finances in general, as well as other risks detailed in the Company’s recent filings on Forms 10-K and 10-Q with SEC. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

     

     

     

     

     


     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    EQUILLIUM, INC.

     

     

    Date: June 13, 2025

    By: /s/ Bruce D. Steel

     

    Bruce D. Steel

     

    President and Chief Executive Officer

     

     

     

     

     


    Get the next $EQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Colabuono Peter

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:50:43 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Demski Martha J

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:47:55 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Pruzanski Mark

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:45:29 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Equillium downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Equillium from Outperform to Market Perform and set a new price target of $1.00 from $3.00 previously

      3/28/25 8:14:37 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Equillium with a new price target

      SVB Leerink reiterated coverage of Equillium with a rating of Outperform and set a new price target of $14.00 from $18.00 previously

      1/5/22 6:36:04 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Equillium with a new price target

      Stifel resumed coverage of Equillium with a rating of Buy and set a new price target of $12.00

      10/29/21 8:33:13 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    SEC Filings

    See more
    • Equillium Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Equillium, Inc. (0001746466) (Filer)

      6/13/25 4:05:42 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Equillium Inc.

      144 - Equillium, Inc. (0001746466) (Subject)

      6/12/25 4:19:18 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Equillium, Inc. (0001746466) (Filer)

      5/22/25 5:15:05 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

      EQ504 protects against gut damage in a mouse model of ulcerative colitis EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7. "Decades of independent re

      5/6/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

      EQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseases EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other immuno-inflammatory therapeutics EQ504 data to be presented in three poster presentations next week at the annual meeting of the American Association of Immunologists (AAI) Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor

      5/1/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces Feedback from the U.S. Food and Drug Administration

      Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for Accelerated Approval, as well as the company's filing for Breakthrough Therapy designation for itolizumab for first-line treatment of acute graft-versus-host disease (aGVHD). The FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway based on the EQUATOR study data. The FDA highlighted

      4/24/25 9:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care